Application of alpha-mangosteen in preparation of medicine for treating cerebral arterial thrombosis

By extracting and purifying α-mangosteen flavonoids, a drug was developed to regulate iron death, which solved the problems of short time window, high bleeding risk and limited efficacy in existing ischemic stroke treatment methods, significantly improving neurological function Recovery and have high safety and extensive clinical application prospects.

CN118903106AInactive Publication Date: 2024-11-08NANTONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411180897.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-27
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing treatment methods for ischemic stroke have many restrictions on the short time window, high bleeding risk, and limited efficacy, and have failed to effectively regulate iron mortality, which limits the reduction effect of brain injury.

Method used

By extracting and purifying α-mangosteen flavonoids and studying its role in regulating the mechanism of ferrody death, a drug containing α-mangosteen flavonoids was developed to inhibit lipid peroxidation and excessive accumulation of iron ions, thereby preventing nerve cell death. Injury caused by ferrous death.

Benefits of technology

It significantly improves the recovery of neurological function, has the advantages of high safety and wide application range, and provides a new treatment strategy for ischemic stroke, improves the treatment effect and safety, and has broad clinical application potential.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903106A_ABST
    Figure CN118903106A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of medicines, and particularly relates to application of alpha-mangostin (alpha-mangostin, alpha-MAG) in preparation of a medicine for treating cerebral arterial thrombosis. Pharmacological experiments show that alpha-mangosteen is used for regulating and controlling a ferroptosis mechanism to inhibit lipid peroxidation, regulate and control iron metabolism and reduce nerve cell injury and has an improvement effect on nerve functions, so that nerve cell injury caused by ferroptosis is effectively prevented, and the alpha-mangosteen can be used for preparing the medicine for treating cerebral arterial thrombosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to application of α-mangosteen flavonoids in regulating ferroptosis and then being used in drugs for treating ischemic stroke. Background Art

[0002] Ischemic stroke is a serious disease caused by interruption of blood supply to the brain, which leads to lack of oxygen and nutrition in brain tissue, thus causing neuronal damage and death. At present, the treatment of ischemic stroke mainly includes thrombolytic therapy, antiplatelet drugs, anticoagulants and neuroprotective agents. However, these treatment methods have many limitations in practical application, such as short time window, high risk of bleeding and limited efficacy. Therefore, finding new treatment methods and drugs has become a hot topic in current medical research.

[0003] At present, the treatment methods for ischemic stroke mainly focus on the following aspects:

[0004] 1) Thrombolytic therapy: This is a method of dissolving blood clots by intravenous or intra-arterial administration, such as using recombinant tissue plasminogen activator (rtPA). Although thrombolytic therapy is effective within a certain time window, its use is strictly limited to a certain time (usually within 4.5 hours after onset) and there is a risk of bleeding and reperfusion injury.

[0005] 2) Antiplatelet and anticoagulant therapy: This type of therapy includes drugs such as aspirin, clopidogrel, and warfarin, which are designed to prevent blood clots from forming. However, long-term use of these drugs may lead to bleeding complications and have limited effects on existing blood clots.

[0006] 3) Neuroprotectants: This class of drugs aims to protect neurons from ischemic damage, such as N-methyl-D-aspartate (NMDA) receptor antagonists and calcium channel blockers. However, many neuroprotectants have failed to show consistent efficacy in clinical trials.

[0007] 4) Free radical scavengers: For example, edaravone, which reduces oxidative stress and cell damage by scavenging free radicals. However, the clinical effect of free radical scavengers still needs further verification.

[0008] Due to the complexity of the pathological mechanism of ischemic stroke, current treatment methods often fail to take into account multiple pathological processes.

[0009] Ferroptosis is a new form of cell death characterized by iron-dependent accumulation of lipid peroxidation and imbalance of the intracellular antioxidant system. In recent years, the role of ferroptosis in various neurological diseases has gradually been revealed, especially in ischemic stroke. Studies have shown that ferroptosis may be one of the key mechanisms leading to neuronal death and brain damage. Therefore, regulating ferroptosis is considered a promising new strategy for the treatment of ischemic stroke. However, most current treatments fail to effectively regulate ferroptosis, thus limiting its effectiveness in alleviating brain damage.

[0010] Although natural products have shown extensive application potential in multiple disease treatment fields, their research and application in the treatment of ischemic stroke are still limited. Mangosteen (Garcinia mangostana) is a tropical fruit whose peel is rich in flavonoids, which have multiple biological activities such as antioxidant, anti-inflammatory, and anti-cancer. In recent years, studies have found that α-mangostin (MAG) exhibits significant neuroprotective effects in in vitro and in vivo experiments, suggesting that it has potential application value in the treatment of neurological diseases. However, the research on α-mangostin in regulating ferroptosis is still in its infancy, and its specific mechanism of action and therapeutic effect in ischemic stroke need further exploration. By in-depth research on the regulatory mechanism of α-mangostin on ferroptosis, the present invention is expected to provide a new theoretical basis and clinical application prospects for the treatment of ischemic stroke. Summary of the invention

[0011] The technical problem to be solved by the present invention is to provide an application of α-mangosteen flavonoids in regulating ferroptosis in the preparation of drugs for treating ischemic stroke. α-mangosteen flavonoids regulates the ferroptosis mechanism to inhibit lipid peroxidation, regulate iron metabolism and reduce nerve cell damage, thereby improving nerve function and effectively preventing nerve cell damage caused by ferroptosis.

[0012] In order to solve the above technical problems, the embodiments of the present invention provide the use of α-mangosteen flavonoids in regulating ferroptosis in the preparation of a drug for treating ischemic stroke.

[0013] Furthermore, α-mangosteen flavonoids are used in the preparation of drugs for regulating ferroptosis mechanisms to treat ischemic stroke.

[0014] α-Mangosteen flavonoids were extracted and prepared, and the composition of α-Mangosteen flavonoids was analyzed and its efficacy in ischemic stroke was tested, followed by formulation development and preclinical research. Its molecular weight is 410.47 and its molecular formula is C 24 H 26 O6, the molecular structure of α-mangosteen flavonoids is shown below:

[0015]

[0016] α-Mangosteen flavonoids have antioxidant and anti-inflammatory effects. They regulate the ferroptosis mechanism, inhibit lipid peroxidation, and reduce excessive accumulation of iron ions, thereby effectively preventing damage to nerve cells caused by ferroptosis.

[0017] Furthermore, the α-mangosteen flavonoids is a flavonoid active ingredient extracted from mangosteen peel.

[0018] An embodiment of the present invention further provides a medicine for treating ischemic stroke, wherein the medicine comprises α-mangosteen flavonoids.

[0019] Furthermore, the medicine comprises α-mangosteen flavonoids and a pharmaceutically acceptable carrier.

[0020] Furthermore, the drug can be prepared into any pharmaceutically acceptable dosage form, including tablets, capsules, granules, oral liquid preparations, injections, and the like.

[0021] The beneficial effects of the above technical solution of the present invention are as follows:

[0022] The present invention proposes a new treatment strategy for ischemic stroke by regulating the ferroptosis mechanism through α-mangosteen flavonoids. Through the extraction and purification of α-mangosteen flavonoids and the study of their mechanism of action, the application prospects of α-mangosteen flavonoids in the treatment of ischemic stroke are systematically demonstrated. The technical solution provided by the present invention can not only significantly improve the patient's neurological function recovery, but also has the advantages of high safety and wide application range, and has broad clinical application potential. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 This is the experimental flow chart of the role of α-α-mangosteen flavonoids (α-MAG) in protecting ischemic stroke by regulating ferroptosis;

[0024] Figure 2 The effect of α-mangosteen flavonoids on neurological dysfunction and brain damage in MCAO / R model rats;

[0025] Figure 3 The effect of α-α-mangosteen flavonoids on neuronal loss in B35 OGD / R or H2O2 model rats;

[0026] Figure 4 The effect of α-mangosteen flavonoids on ferroptosis and oxidative stress in B35 OGD / R or H2O2-induced injured neurons;

[0027] Figure 5To investigate the effects of α-mangosteen flavonoids on ferroptosis and oxidative stress levels in injured neurons induced by ferroptosis agonists Erastin and RSL3. DETAILED DESCRIPTION

[0028] In order to make the technical problems, technical solutions and advantages to be solved by the present invention more clear, a detailed description will be given below with reference to the accompanying drawings and specific embodiments.

[0029] The embodiments of the present invention provide the use of α-mangosteen flavonoids (MAG) in regulating ferroptosis in the preparation of drugs for treating ischemic stroke. The present invention uses modern drug research methods to develop and utilize natural products, combines pharmacodynamic experiments, and through a large number of screenings, finds that α-mangosteen flavonoids has the effect of treating ischemic stroke, and completes the present invention on this basis.

[0030] The dosage forms of the pharmaceutical preparation of the present invention include tablets, capsules, granules, oral liquid preparations, injections, etc.

[0031] Preferably, the drug of the present invention can be made into various solid oral preparations, liquid oral preparations, etc. Pharmaceutically acceptable oral solid preparations include: ordinary tablets, dispersible tablets, enteric-coated tablets, granules, capsules, dripping pills, powders, etc., and oral liquid preparations include oral liquids, emulsions, etc.

[0032] The above-mentioned various dosage forms can be prepared according to conventional processes in the field of pharmaceutical preparations.

[0033] The "pharmaceutically acceptable carrier" of the present invention refers to a conventional drug carrier in the field of pharmaceutical preparations, selected from one or more of fillers, binders, disintegrants, lubricants, suspending agents, wetting agents, pigments, flavoring agents, solvents, and surfactants.

[0034] The α-mangosteen flavonoids used in the present invention are extracted, separated and purified from mangosteen peel as a raw material for extracting α-mangosteen flavonoids. The extraction method is as follows:

[0035] (1) Solvent extraction: Dry and crush the mangosteen peel to an appropriate particle size, and extract it with an organic solvent such as ethanol or methanol at a certain temperature and time. Ultrasonic assisted extraction or heating reflux extraction can be used to improve the extraction efficiency;

[0036] (2) Extraction solution treatment: The extract was filtered through filter paper to remove insoluble matter, and the extract was concentrated to a certain volume using a rotary evaporator.

[0037] (3) Purification process:

[0038] Column chromatography separation: The concentrated extract is separated by silica gel column chromatography, eluted with solvents of different polarities in turn, and the α-mangosteen flavonoids component is collected.

[0039] Recrystallization: The collected flavonoid components are recrystallized and further purified to obtain high-purity α-mangosteen flavonoids.

[0040] The present invention is further described below in conjunction with specific embodiments. Figure 1 shown.

[0041] Example 1: α-Mangosteen flavonoids improves neurological dysfunction and brain damage in MCAO / R model rats

[0042] 1. Animal Model Establishment

[0043] Healthy adult male SD rats weighing 250-300g were selected and randomly divided into an experimental group and a control group. 12.5mg / kg and 25mg / kg of α-MAG were given to the experimental group rats by oral gavage, and the control group rats were given an equal volume of normal saline. The drug was administered once a day for 7 days. Then, the rat ischemic stroke model (such as cerebral ischemia) was established by the middle cerebral artery occlusion / reperfusion (MCAO / R) method. Figure 2 B). The specific steps are to use the rat common carotid artery cannulation technique, insert a thread plug (Beijing Xinong Technology Co., Ltd.) into the right carotid artery, advance it to the middle cerebral artery, and block the blood flow for 1 hour. Then remove the nylon thread, restore blood flow, and complete the reperfusion process.

[0044] 1.1 Grouping

[0045] Sham group, MCAO / R group, MCAO / R+12.5mg / kgα-MAG, MCAO / R+25mg / kgα-MAG group.

[0046] 2. Evaluation of treatment efficacy

[0047] 2.1 Determination of infarct area:

[0048] After 24 hours of reperfusion, the rats were killed and the brain tissue was removed. The cerebral infarction volume was determined using 2,3,5-triphenyltetrazolium chloride (TTC) staining. The specific method was to cut the brain tissue into 2 mm thick coronal slices, immerse it in 1% TTC solution, and incubate it at 37°C for 30 minutes. Take pictures and use image analysis software to measure the infarction volume.

[0049] 2.2 Neurological function score:

[0050] After 24 hours of reperfusion, the rats were evaluated for functional status using the scoring criteria.

[0051] 2.3 Brain tissue pathological analysis:

[0052] After 24 hours of reperfusion, the rats were killed and brain tissues were taken. They were fixed with 4% paraformaldehyde, dehydrated, embedded and sliced, and then HE staining and Nissl staining were performed to observe pathological changes such as neuronal damage and inflammatory infiltration in the cortex and hippocampus of brain tissue. Among them, Nissl staining mainly observes the distribution and morphological changes of Nissl bodies in neurons under a microscope.

[0053] 2.4 Tissue immunofluorescence staining:

[0054] After 24 hours of reperfusion, the rats were killed and brain tissues were removed for frozen section processing. The primary antibody of neuronal marker NeuN was used for incubation for 24 hours, and then the secondary antibody Alexa488 was used for incubation for 1 hour. DAPI was used to stain the cell nucleus for 10 minutes. The images were taken under a confocal microscope and the number of NerN-positive cells was analyzed using Image J software.

[0055] 3. Results Analysis

[0056] The infarct area, neurological function score, pathological analysis results and molecular biological detection results of rats in each group were statistically analyzed using SPSS or GraphPadPrism software. The data were expressed as mean±SEM. The inter-group comparison was performed using t-test or one-way analysis of variance (ANOVA). #VS.Control group, P<0.05, ##VS.ControlP<0.05; *VS.MACO / R group, P<0.05, **VS.MACO / R group, P<0.01, and the differences were considered statistically significant.

[0057] Through the above experimental process, the effect of α-mangosteen flavonoids in improving neurological dysfunction and brain damage in MCAO / R model rats can be comprehensively evaluated. Figure 2 The results of in vivo experiments are shown. Figure 2 A shows that α-mangosteen flavonoids are derived from fresh mangosteen peel, and its molecule is a typical xanthone compound; Figure 2 B is a flow chart of animal experiments and drug treatment; Figure 2 C-2D shows the original results and statistical graphs of TTC staining. Compared with the Sham group, the MCAO / R model group significantly increased the infarct volume, while the MCAO / R+12.5mg / kgα-MAG and MCAO / R+25mg / kgα-MAG groups restored the volume of cerebral infarction. Figure 2 D is a statistical graph of neurological function scores. Compared with the Sham group, the group significantly restored the animal behavior scores. Figure 2 F. Figure 2 G and Figure 2 H. Figure 2I is HE staining, Nissl staining and tissue immunofluorescence and statistical results. Compared with the sham group, the neurons in the CA1, CA2 and DG areas of the hippocampus and the cortex of the MCAO / R model group were lost to varying degrees, while compared with the MCAO / R group, the MCAO / R+12.5mg / kg and MCAO / R+25mg / kgα-MAG groups significantly reduced the damage to brain tissue neurons. This shows that α-MAG at doses of 12.5mg / kg and 25mg / kg significantly reduced the area of ​​cerebral infarction in rats in the MCAO / R model group of ischemic stroke, improved neurological function scores and restored brain tissue damage.

[0058] Example 2: α-Mangosteen flavonoids protects against neuronal loss in B35 OGD / R or H2O2 model rats

[0059] 1. Establishment of cellular oxygen-glucose deprivation and H2O2-induced oxidative stress injury model

[0060] Establishment of OGD / R injury cell model: Rat B35 neuronal cell line was selected, and after 24 hours of recovery culture, the medium was replaced with sugar-free medium and placed in an oxygen-deficient workstation for 16 hours, which is the oxygen-glucose deprivation (OGD) process. Then the cells were taken out and replaced with high-glucose normal medium, and placed in a normal incubator for another 8 hours, which is the reoxygenation (R) process. Figure 3 A).

[0061] Establishment of H2O2-induced oxidative stress injury cell model: Rat B35 neuronal cell line was selected. After 24 hours of recovery culture, 800 μmol / L H2O2 was added to induce oxidative stress injury. After 12 hours of culture, the cells were collected for subsequent experiments.

[0062] 2. Drug treatment

[0063] After preliminary exploration of cell concentration, α-MAG with working concentrations of 1, 5, 10, and 25 nmol / L was added to the cell culture medium 2 hours before OGD / R or H2O2-induced oxidative stress model and acted for 16 hours or 12 hours. Rats in the control group were given an equal volume of DMSO.

[0064] 3. Grouping:

[0065] OGD / R treatment: Control, OGD / R group, OGD / R+1nmol / L α-MAG group, OGD / R+5nmol / L α-MAG group; OGD / R+10nmol / L α-MAG group, OGD / R+25nmol / L α-MAG group.

[0066] H2O2 treatment: Control, H2O2 group, H2O2+1nmol / Lα-MAG group, H2O2+5nmol / Lα-MAG group; H2O2+10nmol / Lα-MAG group, H2O2+25nmol / Lα-MAG group.

[0067] 4. Treatment effect detection

[0068] 4.1 Cell viability assay

[0069] B35 cells were cultured at 1 10 per well. 4 / well in a 96-well culture plate overnight, and then the corresponding treatment (OGD / R or H2O2 stimulation, etc.) was performed. 10 μL of CCK-8 solution (Novozyme) was directly added to 100 μL DMEM, incubated at 37°C for 1 hour, and the absorbance was measured at a wavelength of 450 nm using an automatic microplate reader. The background absorbance value was measured with 100 μL DMEM and 10 μL cell-free solution. Untreated cells were used as the control group, and the relative cell viability was shown as a percentage compared with the control absorbance value.

[0070] 4.2 Observation of cell live / dead (CalceinAM / PI) double staining under fluorescence microscope

[0071] According to the instructions of Calcein / PI Cell Viability and Cytotoxicity Detection Kit (C2015S), after the cells were treated with OGD / R, they were washed twice with PBS, 500 μL of staining working solution was added, and incubated at 37°C in the dark for 30 minutes. After that, the staining working solution was discarded, and after washing twice with PBS, 500 μL of serum-free DMEM was added to each well. Then, the cells were observed under a fluorescence microscope. CalceinAM showed green fluorescence, which represented the cell viability level. PI-positive cells showed red fluorescence, which represented the cell death level.

[0072] 5. Results Analysis

[0073] Through the above experimental procedures, the effect of α-mangosteen flavonoids on OGD / R or H2O2-induced oxidative stress damage can be comprehensively evaluated. Figure 3 Shows the results of in vitro model experiments. Figure 3 A is the flow chart of the establishment of OGD / R damaged cell model and drug treatment; Figure 3 B-3E is a statistical chart of the CCK-8 cell viability results in the OGD / R injury model after reoxygenation at different times, including 0h, 2h, 4h and 8h. Compared with the Control group, the OGD / R model group significantly reduced the viability of B35 cells, while different concentrations of α-MAG (1, 5, 25 and 25nmol / L) significantly increased the viability level of B35 cells. Figure 3E is the original image of the live-death staining results of B35 cells damaged by OGD 16h / R4h. Compared with the Control group, the OGD / R model group significantly reduced the number of B35 live cells and increased the number of B35 dead cells. Compared with the model group OGD / R group, different concentrations of α-MAG (1, 5, 25 and 25nmol / L) significantly increased the number of B35 live cells and reduced the number of B35 dead cells. Figure 3 G is a flow chart of H2O2-induced oxidative stress injury and drug treatment in B35; Figure 3 H and 3I are the results of microscopic cell morphology observation and CCK-8 cell viability test, and the results also showed that 5nmol / L and 50nmol / L α-MAG significantly improved H2O2-induced oxidative stress damage. In short, Figure 3 Overall, α-MAG at a concentration level of nmol / L significantly improved the degree of cell damage induced by OGD / R and H2O2 in the in vitro cell model of ischemic stroke.

[0074] Example 3: α-Mangosteen flavonoids improves ferroptosis and oxidative stress levels in ischemic stroke models in vivo and in vitro

[0075] 1. Ischemic stroke in vivo and in vitro models, drug treatment and grouping are the same as in Example 1 and Example 2

[0076] 2. Treatment effect detection method

[0077] 2.1 ROS level detection

[0078] After the drug treatment of cells, working solution concentrations of DCFH-DA (10 μM) and DHE (10 μM) were added to B35 cells, incubated in an incubator for 20 min, and observed using a fluorescence microscope or flow cytometer.

[0079] 2.2 Molecular biology observation of ferroptosis-related protein expression levels.

[0080] After 24 hours of reperfusion, the rats were killed and their brain tissues were removed and homogenized to extract total protein. The proteins were separated by SDS-PAGE electrophoresis and transferred to the membrane. Specific antibodies were used to detect the expression levels of ferroptosis-related proteins (such as GPX4, FTH1, SLC7A11, etc.) to evaluate the mechanism of α-mangosteen flavonoids in inhibiting ferroptosis.

[0081] 2.3 Transmission electron microscopy observation of cell ferroptosis

[0082] B35 cells were fixed with 2.5% glutaraldehyde at room temperature for 2 h, and then overnight at 4 °C for 24 h. The fixed tissues or cells were then dehydrated with ethanol and embedded in ultrathin sections. The sections were then counterstained with acetoacetyl and lead citrate. Transmission electron microscopy was used to observe and record cells in five different areas.

[0083] 3. Results Analysis

[0084] Through the above experimental process, Figure 4 The results showed that α-mangosteen flavonoids can inhibit ferroptosis damage in ischemic stroke models in vivo and in vitro. Figure 4 A and Figure 4 B shows the microscopic observation and flow cytometry detection of ROS levels in H2O2-induced damage of B35 cells and statistical analysis charts. Compared with the Normal group, the H2O2 group significantly increased the level of reactive oxygen species ROS, while 1nmol / L and 5nmol / L α-MAG restored the ROS level. Figure 4 C-4D shows the results of WB protein detection of ferroptosis-related molecules. The main function of FTH1 (Ferritin Heavy Chain 1) is to store iron and prevent excessive accumulation of iron and the resulting cytotoxicity. The main function of TFR1 (Transferrin Receptor 1) is to bind to the transfer protein carrying iron and transport iron into the cell, thereby increasing the intensity of ferroptosis. Figure 4 C-4D showed that compared with the Control group, the MCAO / R group reduced the expression of ferroptosis-related protein FTH1 and increased the expression of TFR1, reduced stored iron, and increased the accumulation of intracellular iron, thereby aggravating the degree of ferroptosis. However, α-MAG reduced ferroptosis by reducing the expression of FTH1. Figure 4 In the results of C-4D, the expressions of SLC7A11 and ACSL4 both showed an upward trend, which alleviated the occurrence of ferroptosis to a certain extent. This may be a feedback result of the body's maintenance of oxidative balance during stroke. In the cell OGD / R and H2O2-induced injury models, Figure 4 E and 4F showed that α-MAG increased the protein expression of GPX4, SLC7A11, and FTH1, thereby inhibiting the extent of ferroptosis. Figure 4 G further used transmission electron microscopy to observe that the OGD / R group reduced mitochondrial cristae and increased mitochondrial density, thereby increasing mitochondrial ferroptosis damage. Compared with the OGD / R group, α-MAG significantly inhibited mitochondrial ferroptosis damage. In summary, Figure 4 Overall, α-MAG can inhibit the occurrence of oxidative stress and ferroptosis in ischemic stroke.

[0085] Example 4: α-Mangosteen flavonoids reduce ferroptosis and oxidative stress levels in damaged neurons induced by ferroptosis agonists RSL3 and Erastin

[0086] Ferroptosis agonists RSL3 and Erastin were used to induce ferroptosis in the neuronal cell line B35. α-Mangosteen flavonoids were used for drug treatment and subsequent specific experimental detection methods were the same as above, mainly including: flow cytometry, fluorescence microscopy, Western blot, RT-qPCR and other technologies to detect cell survival rate, expression of ferroptosis-related genes (such as GPX4, SLC7A11) and WB experimental detection of peroxide levels.

[0087] Figure 5 A: Optical microscopy observation shows that α-MAG can restore RSL3-induced cell morphological damage; Figure 5 B is the live-dead cell staining result, showing that α-MAG significantly reduced dRSL3-induced cell damage and increased the number of live cells. Figure 5 C-5D indicate that α-MAG enhances the viability of cell damage induced by RSL3 and Erastin, respectively. Figure 5 E, 5F show that α-MAG reduced the level of oxidative stress in RSL3-induced cell damage. Figure 5 G is the result of microscopic observation by transmission electron microscopy, showing that α-MAG significantly reduced RSL3-induced ferroptotic mitochondrial damage. Figure 5 This indicates that α-mangosteen flavonoids reduces the levels of ferroptosis and oxidative stress in damaged neurons induced by ferroptosis agonists RSL3 and Erastin.

[0088] The present invention relates to the use of α-mangosteen flavonoids in regulating ferroptosis in the preparation of a drug for treating ischemic stroke, and the technical solution thereof brings the following beneficial effects:

[0089] (1) Innovative treatment strategy: This invention combines α-mangosteen flavonoids with the ferroptosis mechanism for the first time to develop a new drug for the treatment of ischemic stroke. Traditional treatments for ischemic stroke mainly focus on blood flow restoration and anticoagulation, while this invention provides new ideas and options for the treatment of ischemic stroke by regulating ferroptosis, a key pathological process, and is expected to significantly improve the treatment effect.

[0090] (2) Significant neuroprotective effect: α-Mangosteen flavonoids in the present invention exhibits strong antioxidant and iron metabolism regulating abilities, can effectively inhibit lipid peroxidation, and reduce nerve cell damage caused by ferroptosis. Experimental results show that the drug of the present invention can significantly reduce cell apoptosis in ischemic brain injury areas, promote the recovery of neurological function, and thus improve the quality of life of patients.

[0091] (3) High safety of natural ingredients: α-mangosteen flavonoids, as a flavonoid compound derived from natural plants, has good biocompatibility and safety. Compared with chemically synthesized drugs, the drug of the present invention may reduce the occurrence of side effects due to its natural source, and has higher safety and patient compliance.

[0092] (4) Multiple mechanisms of action: The present invention not only exerts a neuroprotective effect by inhibiting ferroptosis, but also intervenes in the process of ischemic stroke from multiple pathological links through multiple mechanisms such as enhancing the antioxidant defense system and regulating iron metabolism. This multi-target mechanism of action is expected to improve the therapeutic effect of the drug and reduce the risk of single-target drugs easily developing drug resistance.

[0093] (5) Broad application prospects: The drug of the present invention has good therapeutic potential. In addition to being used for ischemic stroke, it may also be extended to other neurodegenerative diseases or acute brain injuries involving ferroptosis mechanisms, such as Parkinson's disease and Alzheimer's disease, thereby further expanding its market value and scope of application.

[0094] (6) Providing a basis for subsequent research: The research results of the present invention lay a foundation for the further development of α-mangosteen flavonoids in the medical field, especially in preclinical research and dosage form development. The technical solution of the present invention provides a clear direction for subsequent pharmacological research, toxicological research, dosage form optimization, etc., and is expected to accelerate the clinical transformation process of α-mangosteen flavonoids drugs.

[0095] In summary, the present invention not only provides a new and effective way to treat ischemic stroke through the innovative application of α-mangosteen flavonoids to regulate ferroptosis, but also has broad clinical application prospects and high market potential, significantly improving the effectiveness and safety of existing treatment methods.

[0096] The above is a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Application of α-α-mangosteen flavonoids in the preparation of drugs for the treatment of ischemic stroke.

2. The use according to claim 1, It is characterized in that Application of α-mangosteen flavonoids in the preparation of drugs for regulating ferroptosis mechanism to treat ischemic stroke.

3. The use according to claim 1, It is characterized in that The α-mangosteen flavonoids are flavonoid active ingredients extracted from mangosteen peel.

4. A drug for treating ischemic stroke, It is characterized in that The medicine includes α-mangosteen flavonoids.

5. The drug according to claim 4, It is characterized in that The medicine comprises α-mangosteen flavonoids and a pharmaceutically acceptable carrier.

6. The drug according to claim 5, It is characterized in that The dosage form of the drug is an oral dosage form or an injection.

7. The drug according to claim 6, It is characterized in that The oral dosage form is selected from capsules, tablets, granules or oral liquids.